APA (7th ed.) Citation

Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S, & Potestio L. (2024). Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study. Dove Medical Press.

Chicago Style (17th ed.) Citation

Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S, and Potestio L. Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study. Dove Medical Press, 2024.

MLA (9th ed.) Citation

Megna M, et al. Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study. Dove Medical Press, 2024.